Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases

Varování

Publikace nespadá pod Ústav výpočetní techniky, ale pod Lékařskou fakultu. Oficiální stránka publikace je na webu muni.cz.
Autoři

KUBEŠ Václav KŘEN Leoš SOKOL Filip MICHALKA Jozef MUŽÍK Jan ARPÁŠ Tomáš KŘENOVÁ Zdenka KRÁL Zdeněk

Rok publikování 2023
Druh Článek v odborném periodiku
Časopis / Zdroj In vivo
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://iv.iiarjournals.org/content/37/4/1735
Doi http://dx.doi.org/10.21873/invivo.13261
Klíčová slova Classic Hodgkin lymphoma; PD-L1 expression; treatment; overall survival; relapse
Popis Background/Aim: Classic Hodgkin lymphoma (cHL) is a common B-cell malignancy. Despite the good prognosis, in some patients the standard chemotherapy and radiotherapy-based approach does not lead to long-term remission, and these patients eventually relapse. Moreover, the primary refractory disease is of major concern regarding prognosis. Patients and Methods: We performed a retrospective analysis to evaluate PD-L1 expression in 120 patients with classic Hodgkin lymphoma (cHL). Results: The median follow-up of the entire group of patients was 90 months. After initial therapy, complete remission was achieved in 113 (94.2%) patients. During the follow-up, cHL relapse/refractory disease was reported in 23 (19.2%) cases. A total of five patients died during the follow-up period, all from cHL progression. When determining PD-L1 expression on Hodgkin-Reed-Sternberg (HRS) cells, 37 cases (30.8%) were evaluated as negative, and 83 cases (69.2%) as positive. In the negative PD-L1 group of patients, no cHL relapse/refractory disease was observed during the follow -up period. However, out of 83 patients with positive PD-L1 expression on HRS cells, 23 (28%) showed relapse/refractory cHL. Conclusion: A significantly higher relapse rate was observed in PD-L1-positive patients diagnosed with cHL.
Související projekty:

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info